Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Review

Risks and benefits of TIPS in HCC and other liver malignancies: a literature review

Authors: Anna Fichtl, Thomas Seufferlein, Eugen Zizer

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Transjugular intrahepatic portosystemic shunt (TIPS) is a well-validated treatment option for clinically significant portal hypertension (CSPH) in the context of liver cirrhosis. Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. Contraindications for TIPS include severe right heart failure, hepatic encephalopathy, and sepsis. However, the role of liver malignancy in TIPS is debatable. Mostly, primary liver malignancies such as hepatocellular carcinoma (HCC) emerge from advanced liver diseases. Coexisting portal hypertension in HCC often results in limited treatment options and a poor prognosis.

Summary

Previous studies have shown that TIPS implantation in patients with HCC is technically feasible and is usually not associated with major adverse events. Furthermore, TIPS may help in bridging the time to liver transplantation in early HCC and allow for locoregional treatment in advanced HCC. However, several studies suggest that seeding tumour cells to the lungs by TIPS placement might worsen the prognosis.

Conclusions

TIPS placement in patients with coexisting liver malignancy remains a case-by-case decision, and there is no profound evidence allowing general recommendations. This review aims to provide a state-of-the-art overview of the potential risks and benefits of TIPS placement in patients with liver malignancies.
Literature
1.
Sauerbruch T, Schierwagen R, Trebicka J. Managing portal Hypertension in patients with liver Cirrhosis [version 1; referees: 2 approved]. F1000Research. 2018;7.
2.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII – renewing consensus in portal Hypertension. J Hepatol. 2022;76:959–74.PubMedCrossRef
3.
Horhat A, Bureau C, Thabut D, Rudler M. Transjugular intrahepatic portosystemic shunt in patients with Cirrhosis: indications and posttransjugular intrahepatic portosystemic shunt Complications in 2020. United Eur Gastroenterol J. 2021;9(2):203–8.CrossRef
4.
Sidali S, Trépo E, Sutter O, Nault JC. New concepts in the treatment of hepatocellular carcinoma. United Eur Gastroenterol J. 2022;10(7):765–74.CrossRef
5.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7:6.PubMedCrossRef
6.
Larrey E, Cluzel P, Rudler M, Goumard C, Damais-Thabut D, Allaire M. TIPS for patients with early HCC: a bridge to liver transplantation. Clin Res Hepatol Gastroenterol. 2022;46(8):e6.CrossRef
7.
Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with Cirrhosis and refractory Ascites: a randomized trial. J Hepatol. 1996;25:135–44.PubMedCrossRef
8.
Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory Ascites in Cirrhosis. Gastroenterology. 2002;123(6):1839–47.PubMedCrossRef
9.
Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in Cirrhosis with severe Ascites. Hepatology. 2004;40(3):629–35.PubMedCrossRef
10.
Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, et al. Transjugular intrahepatic portosystemic shunt using covered stents for refractory Ascites: midterm results. J Vasc Interv Radiol. 2007;18(7):858–65.
11.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with Cirrhosis and recurrent Ascites. Gastroenterology. 2017;152(1):157–63e7.PubMedCrossRef
12.
Dong H, Zhang C, Li Z, Yang H, Wang Y, Liu J, et al. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: a preliminary study. J Cancer Res Ther. 2021;17(3):784–9.PubMedCrossRef
13.
Liu L, Zhao Y, Qi X, Cai G, He C, Guo W, et al. Transjugular intrahepatic portosystemic shunt for symptomatic portal Hypertension in hepatocellular carcinoma with portal vein Tumor Thrombosis. Hepatol Res. 2014;44(6):621–30.PubMedCrossRef
14.
Bettinger D, Knüppel E, Euringer W, Spangenberg HC, Rössle M, Thimme R, et al. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2015;41(1):126–36.PubMedCrossRef
15.
Qiu Z, Wang G, Yan H, Qi H, Zuo M, Wang G, et al. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal Hypertension. Eur Radiol. 2022;32(10):6777–87.PubMedPubMedCentralCrossRef
16.
Luo SH, Chu JG, Huang H, Yao KC. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World J Clin Cases. 2019;7(13):1599–610.PubMedPubMedCentralCrossRef
17.
Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, et al. Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of gastric variceal rebleeding in patients with Hepatocellular Carcinoma: a Multicenter Retrospective Study. J Vasc Interv Radiol. 2021;32(7):963–9.PubMedCrossRef
18.
Yan H, Qiu Z, Xiang Z, Feng K, Huang M, Gao F. TIPS improves outcomes in patients with HCC and symptomatic portal Hypertension: a multi-institution experience. Cancer Imaging. 2022;22(1).
19.
García-Pagán JC, Caca K, Bureau C, Laleman W, Luca A, Abraldes JG, et al. Early Use of TIPS in patients with Cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9.PubMedCrossRef
20.
Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced Cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(8):587–98.PubMedCrossRef
21.
Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2019;69(1):282–93.PubMedCrossRef
22.
Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al. Identifying optimal candidates for early TIPS among patients with Cirrhosis and acute variceal bleeding: a multicentre observational study. Gut. 2019;68(7):1297–310.PubMedCrossRef
23.
Lv Y, Bai W, Zhu X, Xue H, Zhao J, Zhuge Y et al. CLIF-C AD score predicts survival benefit from pre-emptive TIPS in individuals with child-pugh B Cirrhosis and acute variceal bleeding. JHEP Rep. 2022;100621.
24.
Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99(11):2158–65.PubMedCrossRef
25.
Lee YR, Park SY, Tak WY. Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma. Gut Liver. 2020;14(4):500–8.PubMedCrossRef
26.
Niekamp A, Kuban JD, Lee SR, Yevich S, Metwalli Z, McCarthy CJ, et al. Transjugular Intrahepatic Portosystemic shunts reduce Variceal bleeding and improve survival in patients with Cirrhosis: a Population-based analysis. J Vasc Interv Radiol. 2020;31(9):1382–91e2.PubMedCrossRef
27.
Zhou Y, Zhang W, Zhang Z, Luo J, Gu J, Liu Q, et al. PTFE-covered TIPS is an effective treatment for secondary preventing variceal rebleeding in cirrhotic patients with high risks. Eur J Gastroenterol Hepatol. 2020;32(9):1235–43.PubMedPubMedCentralCrossRef
28.
Ripoll C, Genescà J, Araujo IK, Graupera I, Augustin S, Tejedor M, et al. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology. 2013;58(6):2079–88.PubMedCrossRef
29.
Davies RP, Richard G, Sissonsj J, Mclntosh NA. CardioVascular and lnterventional Transjugular Intrahepatic Portocaval Shunt (TIPS) and hepatic vein-to-Caval Stenting as Salvage Treatment of Portal Hypertension Secondary to Neoplasm. Cardiovasc Intervent Radiol. 1993;16:105–8.PubMedCrossRef
30.
Serafini FM, Zwiebel B, Black TJ, Carey LC, Rosemurgy AS. Transjugular Intrahepatic Portosystemic Stent Shunt in the treatment of Variceal Bleeding in Hepatocellular Cancer. Dig Dis Sci. 1997;42(1):59–65.PubMedCrossRef
31.
Chen Y, Ma X, Zhang X, Luo J, An L, Zhang Y, et al. Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus β-blocker. Hepatol Int. 2022;16(6):1379–89.PubMedCrossRef
32.
Young S, Bermudez J, Zhang L, Rostambeigi N, Golzarian J. Transjugular intrahepatic portosystemic shunt (TIPS) placement: a comparison of outcomes between patients with hepatic hydrothorax and patients with refractory Ascites. Diagn Interv Imaging. 2019;100(5):303–8.PubMedCrossRef
33.
Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with Cirrhosis. Am J Gastroenterol. 2010;105(3):635–41.PubMedCrossRef
34.
Lim J, Kim Hil, Kim E, Kim J, An J, Chang S, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer. 2021;21(1):11.PubMedPubMedCentralCrossRef
35.
Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, et al. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein Tumor Thrombosis with cirrhotic portal Hypertension. World J Gastrointest Surg. 2022;14(6):567–79.PubMedPubMedCentralCrossRef
36.
Zhao JB, Feng C, Zhu QH, He XF, Li YH, Chen Y. Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein Tumor Thrombosis. World J Gastroenterol. 2014;20(6):1602–7.PubMedPubMedCentralCrossRef
37.
Jiang ZB, Shan H, Shen XY, Huang MS, Li ZR, Zhu, Kang-Shun, et al. Transjugular intrahepatic portosystemic shunt for palliative treatment of portal Hypertension secondary to portal vein Tumor Thrombosis. World J Gastroenterol. 2004;10(13):1881–4.PubMedPubMedCentralCrossRef
38.
Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40(9):1372–82.PubMedCrossRef
39.
Zhao H, Tsauo J, Zhang X, Gong T, Li J, Li X. Transjugular intrahepatic portosystemic shunt creation for portal Hypertension in patients with hepatocellular carcinoma: a systematic review. Int J Gastrointest Interv. 2018;7(3):167–71.CrossRef
40.
Yan J, Li T, Deng M, Fan H. Ruptured Hepatocellular Carcinoma: what do interventional radiologists need to know? Front Oncol. 2022;12.
41.
Sellers CM, Nezami N, Schilsky ML, Kim HS. Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: current state and future directions. Transpl Rev (Orlando). 2019;33:64–71.CrossRef
42.
Yao J, Zuo L, An G, Yue Z, Zhao H, Wang L, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal Hypertension. J Gastrointest Liver Dis. 2015;24(3):301–7.CrossRef
43.
44.
Nardelli S, Bellafante D, Ridola L, Faccioli J, Riggio O, Gioia S. Prevention of post-TIPS hepatic encephalopathy: the search of the ideal candidate. Metab Brain Dis. 2023;38(5):1729–36.PubMedCrossRef
45.
Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal Hypertension. Gut. 2020;69(7):1173–92.PubMedCrossRef
46.
Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, et al. Sarcopenia is risk factor for development of hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2017;15(6):934–6.PubMedCrossRef
47.
Jiang C, Wang Y, Fu W, Zhang G, Feng X, Wang X, et al. Association between Sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis. Front Nutr. 2022;9:978110.PubMedPubMedCentralCrossRef
48.
Zou X, Xue M, Li J. Combined use of transjugular intrahepatic portosystemic shunt and transarterial chemoembolization in the treatment of esophageal and gastric variceal bleeding: a retrospective study of 80 patients with hepatocellular carcinoma and portal Hypertension. Med Sci Monit. 2021;27:e934436.PubMedPubMedCentralCrossRef
49.
Chang L, Wang W, Jiang N, Rao F, Gong C, Wu P, et al. Dexamethasone prevents TACE-induced adverse events: a meta-analysis. Medicine. 2020;99(47):e23191.PubMedPubMedCentralCrossRef
50.
Lee HL, Lee SW. The role of transjugular intrahepatic portosystemic shunt in patients with portal Hypertension: advantages and pitfalls. Clin Mol Hepatol. 2022;28:121–34.PubMedCrossRef
51.
Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, et al. Hepatic toxicity after selective chemoembolization is associated with decreased survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2021;216(5):1283–90.PubMedCrossRef
52.
Kohi MP, Fidelman N, Naeger DM, Laberge JM, Gordon RL, Kerlan RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24(1):68–73.PubMedCrossRef
53.
Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36(5):1336–43.PubMedCrossRef
54.
Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol. 2021;27(5):671–6.PubMedPubMedCentralCrossRef
55.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH. Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: a systematic review of efficacy and Safety Data. Hepatology. 2016;64(1):106–16.PubMedCrossRef
56.
Fan W, Guo J, Zhu B, Wang S, Yu L, Huang W, et al. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol. 2021;31:8291–301.PubMedPubMedCentralCrossRef
57.
Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, et al. Imaging changes and clinical Complications after drug-eluting bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. AJR Am J Roentgenol. 2021;217(4):933–44.PubMedCrossRef
58.
Padia SA, Chewning RH, Kogut MJ, Ingraham CR, Johnson GE, Bhattacharya R, et al. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic shunts. Cardiovasc Intervent Radiol. 2015;38(4):913–21.PubMedCrossRef
59.
Thabut D, Kudo M. Treatment of portal Hypertension in patients with HCC at the era of Baveno VII. J Hepatol. 2022;78(3):658–62.PubMedCrossRef
60.
Bjosrneboe M, Andersen JR, Christensen U, Skinhosj P, Jensen OM. Does a portal-systemic shunt increase the risk of primary hepatic carcinoma in Cirrhosis of the Liver? Scand J Gastroenterol. 1985;20(1):59–64.CrossRef
61.
Wei J, Li H, Li C. Investigating the risk factors of hepatocellular carcinoma and survival analysis for Cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal Hypertension. J Cancer Res Ther. 2018;14(4):826–32.PubMedCrossRef
62.
Krumeich LN, Mancinelli J, Cucchiara A, Eddinger K, Aufhauser D, Goldberg DW, et al. Occult Hepatocellular Carcinoma Associated with Transjugular Intrahepatic Portosystemic shunts in Liver Transplant recipients. Liver Transpl. 2021;27(9):1248–61.PubMedPubMedCentralCrossRef
63.
Hüsing-Kabar A, Meister T, Köhler M, Domschke W, Kabar I, Wilms C, et al. Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased? United Eur Gastroenterol J. 2018;6(3):413–21.CrossRef
64.
Chang J, Dumitrache A, Böhling N, Abu-Omar J, Meyer C, Strobel D, et al. Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with Cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). Sci Rep. 2020;10(1):20682.PubMedPubMedCentralCrossRef
65.
Chen B, Pang L, Chen H bin, Wu DB, Wang YH, Chen EQ. TIPS is not associated with a higher risk of developing hcc in cirrhotic patients: A systematic review and meta-analysis. J Clin Transl Hepatol. 2019;7(3):232–7.
66.
Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung Metastasis: a population-based study. Cancer Manage Res. 2019;11:2759–68.CrossRef
67.
Wallace M, Swaim M. Transjugular intrahepatic portosystemic shunts through hepatic Neoplasms. J Vasc Interv Radiol. 2003;14(4):501–7.PubMedCrossRef
68.
Wu CC, Ho WL, Chen JT, Tang CS, Yeh DC, Liu TJ. Mesohepatectomy for centrally located Hepatocellular Carcinoma: an Appraisal of a Rare Procedure. J Am Coll Surg. 1999;188:508–15.PubMedCrossRef
69.
70.
Wallace MJ, Madoff DC, Ahrar K, Warneke CL. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting. Cancer. 2004;101(2):337–45.PubMedCrossRef
71.
Geeroms B, de Hertogh G, Vanslembrouck R, Wildiers H, Nevens F, Maleux G. Transjugular Intrahepatic Portosystemic Shunt for the treatment of Portal Hypertension-Induced Refractory Ascites due to metastatic Carcinomatous Liver Disease. J Vasc Interv Radiol. 2018;29(12):1713–6.PubMedCrossRef
72.
Shreve LA, O’Leary C, Clark TWI, Stavropoulos SW, Soulen MC. Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis. J Gastrointest Oncol. 2022;13(1):279–87.PubMedPubMedCentralCrossRef
73.
Jha P, Poder L, Wang ZJ, Westphalen AC, Yeh BM, Coakley FV. Radiologic mimics of Cirrhosis. Am J Roentgenol. 2010;194(4):993–9.CrossRef
74.
75.
Kang SP, Taddei T, McLennan B, Lacy J. Pseudocirrhosis in a Pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with early recognition and management. World J Gastroenterol. 2008;14(10):1622–4.PubMedPubMedCentralCrossRef
76.
Shinoda T, Tanahashi T, Sakuratani T, Ota M, Fujibayashi S, Kiriyama S, et al. Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: a case report. Mol Clin Oncol. 2022;16(1):11.PubMedCrossRef
77.
Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, et al. Clinical characteristics and outcomes in patients with metastatic Breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2023;197:137–48.PubMedCrossRef
78.
Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal Hypertension. World J Gastroenterol. 2015;21(43):12439–47.PubMedPubMedCentralCrossRef
Metadata
Title
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review
Authors
Anna Fichtl
Thomas Seufferlein
Eugen Zizer
Publication date
01-12-2023

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue

Research

Non-alcoholic fatty liver disease and socioeconomic determinants in an Iranian cohort study

Research

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer

Research

Convenient method to improve efficiency of lymph node examination after gastrectomy with D2 lymphadenectomy for gastric cancer

Research

Establishing machine learning models to predict the early risk of gastric cancer based on lifestyle factors

Research

An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study

Research

Diagnostic performance of the normal range of gastrin calculated using strict criteria based on a combination of serum markers and pathological evaluation for detecting gastritis: a retrospective study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits